Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) EVP Sells 61,582 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Erik Phelps sold 61,582 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $82.36, for a total value of $5,071,893.52. Following the sale, the executive vice president now owns 153,080 shares of the company’s stock, valued at approximately $12,607,668.80. This represents a 28.69 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Erik Phelps also recently made the following trade(s):

• On Wednesday, February 5th, Erik Phelps sold 5,934 shares of Tempus AI stock. The shares were sold at an average price of $67.57, for a total value of $400,960.38.

Tempus AI Stock Down 11.2 %

NASDAQ:TEM opened at $68.09 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $91.45. The firm has a fifty day simple moving average of $50.29 and a 200-day simple moving average of $51.72.

Analyst Ratings Changes

A number of brokerages recently weighed in on TEM. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and raised their price objective for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Loop Capital lowered their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. TD Cowen reaffirmed a “buy” rating and issued a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Bank of America increased their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a report on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and an average price target of $58.55.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. ARK Investment Management LLC increased its holdings in shares of Tempus AI by 132.1% in the fourth quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock valued at $186,343,000 after purchasing an additional 3,141,487 shares during the period. NEA Management Company LLC boosted its position in Tempus AI by 17.8% in the third quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock valued at $304,846,000 after buying an additional 813,169 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in Tempus AI by 166.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after buying an additional 2,021,394 shares during the period. Nikko Asset Management Americas Inc. raised its position in Tempus AI by 166.0% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after buying an additional 2,021,394 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in Tempus AI by 240.5% during the 4th quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company’s stock valued at $93,251,000 after acquiring an additional 1,950,862 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.